why choose us

Clinical Trials Search

Showing 10,630 of 132,366 result(s)
CAR T-cell Therapy in Patients With Renal Dysfunction

Status: NOT_YET_RECRUITING

Condition: Non-hodgkin Lymphoma,B Cell

Interventions: Received IV on Days -5 to -3 before CAR T cell therapy

Date: 2023-06-09

A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP)

Status: NOT_YET_RECRUITING

Condition: Pre-Gestational Diabetes

Interventions: The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge

Date: 2023-06-09

Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma

Status: NOT_YET_RECRUITING

Condition: Hepatocellular Carcinoma

Interventions: Atezolizumab (1200mg) and Bevacizumab (15mg;kg) are administered to patients once for each cycle with 3-week intervals, and additional radiothera

Date: 2023-06-09

Influence of Manual Diaphragm Release on Pulmonary Functions in Women With COVID-19

Status: COMPLETED

Condition: COVID-19 Pneumonia

Interventions: manual diaphragmatic release technique combined with breathing exercise

Date: 2023-06-09

Phase I;II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Status: NOT_YET_RECRUITING

Condition: Neoplasms

Interventions: Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.

Date: 2023-06-09

COVID Infection in Pediatric Surgical Patient

Status: Completed

Condition: COVID-19

Interventions: COVID-19 rapid antigen testing of nasal swab

Date: 2023-06-09

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure

Status: NOT_YET_RECRUITING

Condition: Urgent Surgery

Interventions: Andexanet is a recombinant version of human FXa

Date: 2023-06-09

Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Status: NOT_YET_RECRUITING

Condition: Non-Small Cell Lung Cancer

Interventions: 1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.

Date: 2023-06-09

PRF Therapy for Pocket Reduction

Status: COMPLETED

Condition: Periodontal Pocket

Interventions: The pockets were treated with scaling and root planing (SRP) along with the simultaneous insertion of a Platelet Rich Fibrin (PRF) membrane.
Bloo

Date: 2023-06-08

Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer

Status: COMPLETED

Condition: Gastric Cancer (Diagnosis)

Interventions: The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour aft

Date: 2023-06-08